Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a protein drink rebuild strength in cirrhosis?

NCT ID NCT06573229

Symptom relief Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

Researchers test whether a daily nutritional supplement improves muscle function in people with cirrhosis and sarcopenia, a condition of muscle loss. Thirty adults with cirrhosis and a risk of sarcopenia receive either the supplement or a placebo for two months, along with standard nutritional counseling. The study measures changes in physical function, body composition, quality of life, and blood metabolites.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A nutritional supplement containing whey protein, vitamin D, carnitine, HMB, perilla, arginine, coenzyme Q10, and inositol
What this could lead to
If the supplement helps, it could offer a low-risk way to support muscle strength and daily function in people with cirrhosis.
What could go wrong
This is a small, short pilot study of 30 people, so any benefits may be modest or not hold up in larger trials. Supplements can also cause digestive upset or interact with other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Aug 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients affected by Liver cirrhosis * at any stage of Child (A-B-C) with or without hepatocarcinoma * SARC-F suggestive of risk of sarcopenia * Age \> 18 years * Ability to perform Liver Frailty Index test * Informed consent to participate in the study. Exclusion Criteria: * SARC-F not suggestive of sarcopenia * inability to perform Liver Frailty Index test * absence of informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis, liver are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver kwashiorkor Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhosis, liver Malnutrition; protein Sarcopenia

Contacts and locations

Locations

  • Emanuele Rinninella

    Rome, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.